5TA6

Crystal structure of PLK1 in complex with a novel 5,6-dihydroimidazolo[1,5-f]pteridine inhibitor.

5TA6 の概要

• エントリーDOI: 10.2210/pdb5ta6/pdb
• 関連するPDBエントリー: 5TA8
• 分子名称: Serine/threonine-protein kinase PLK1, 4-{[(6R)-7-cyano-5-cyclopentyl-6-ethyl-5,6-dihydroimidazo[1,5-f]pteridin-3-yl]amino}-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide, ZINC ION, ... (4 entities in total)
• 機能のキーワード: plk1 inhibitor, kinase, structure-based drug design, antitumor activity, transferase-transferase inhibitor complex, transferase/transferase inhibitor
• 由来する生物種: Homo sapiens (Human)
• 細胞内の位置: Nucleus: P53350
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 41203.99

構造登録者

Skene, R.J.,Hosfield, D.J. (登録日: 2016-09-09, 公開日: 2017-02-22, 最終更新日: 2024-03-06)

主引用文献

Kiryanov, A.,Natala, S.,Jones, B.,McBride, C.,Feher, V.,Lam, B.,Liu, Y.,Honda, K.,Uchiyama, N.,Kawamoto, T.,Hikichi, Y.,Zhang, L.,Hosfield, D.,Skene, R.,Zou, H.,Stafford, J.,Cao, X.,Ichikawa, T.
Structure-based design and SAR development of 5,6-dihydroimidazolo[1,5-f]pteridine derivatives as novel Polo-like kinase-1 inhibitors.
Bioorg. Med. Chem. Lett., 27:1311-1315, 2017

PubMed Abstract: Using structure-based drug design, we identified a novel series of 5,6-dihydroimidazolo[1,5-f]pteridine PLK1 inhibitors. Rational improvements to compounds of this class resulted in single-digit nanomolar enzyme and cellular activity against PLK1, and oral bioavailability. Compound 1 exhibits >7 fold induction of phosphorylated Histone H3 and is efficacious in an in vivo HT-29 tumor xenograft model.

PubMed: 28169164
DOI: 10.1016/j.bmcl.2016.10.009

実験手法

X-RAY DIFFRACTION (2.5 Å)